Itch: From mechanism to (novel) therapeutic approaches - 06/11/18
, Jordan Daniel Rosen, BS, Takashi Hashimoto, MD, PhDAbstract |
Itch is a common sensory experience that is prevalent in patients with inflammatory skin diseases, as well as in those with systemic and neuropathic conditions. In patients with these conditions, itch is often severe and significantly affects quality of life. Itch is encoded by 2 major neuronal pathways: histaminergic (in acute itch) and nonhistaminergic (in chronic itch). In the majority of cases, crosstalk existing between keratinocytes, the immune system, and nonhistaminergic sensory nerves is responsible for the pathophysiology of chronic itch. This review provides an overview of the current understanding of the molecular, neural, and immune mechanisms of itch: beginning in the skin, proceeding to the spinal cord, and eventually ascending to the brain, where itch is processed. A growing understanding of the mechanisms of chronic itch is expanding, as is our pipeline of more targeted topical and systemic therapies. Our therapeutic armamentarium for treating chronic itch has expanded in the last 5 years, with developments of topical and systemic treatments targeting the neural and immune systems.
Le texte complet de cet article est disponible en PDF.Key words : Itch, pruritus, treatment, mechanism, pathophysiology, management
Abbreviations used : ACC, AD, Bhlhb5, BTX, CGRP, GPCR, GRP, GRPR, JAK, KOR, LPA, MOR, Mrgpr, NaV, NGF, NK, NK1R, PAR, PCC, PF, SP, STAT, TrkA, TRPA, TRPM, TRPV, TSLP
Plan
Vol 142 - N° 5
P. 1375-1390 - novembre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
